Introduction
It has been reported that amplification at 11q13 is involved in esophageal squamous cell carcinoma (ESC) as well as in several other types of solid tumors (Yoshida et al. 1993; Schuuring 1995; Schwab 1998 ). In addition, there is evidence that this amplification is associated with malignant phenotypes of ESC, such as invasiveness, metastasis, and poor prognosis (Yoshida et al. 1993; Adelaide et al. 1995; Shinozaki et al. 1996) . Within the 11q13 amplicon, CCND1 and EMS1 are the only genes known to be both amplified and overexpressed, thereby making them target genes in ESC as well as other tumors exhibiting the 11q13 amplification (Schuuring 1995; Hui et al. 1997) . However, this amplicon spans a 3-5 Mb region, and comprises numerous genes that have not been well characterized thus far (Map Viewer, http://www.ncbi.nlm.nih.gov/cgi-bin/Entretz/ map-search).
The chromosomal band 11q13 is frequently involved in chromosomal translocations in various hematological malignancies (Mitelman et al. 1997) , such as the translocation t(11;14)(q13;q32) in a subset of B-cell malignancies, especially in non-Hodgkin lymphomas and multiple myeloma (MM) (Mitelman et al. 1997; Ronchetti et al. 1999; Chesi et al. 2000) . This type of recurrent chromosomal alteration juxtaposes CCND1 to the IgH-5Ј Eµ enhancer at 14q34.2, resulting in the deregulation of CCND1 expression, which is considered to be a critical molecular event in the pathogenesis of t(11;14) hematological malignancies (Nakamura et al. 1997) . Through application of the NIH/3T3 tumorigenicity assay, MYEOV was recently identified as a novel transforming gene and mapped at 11q13 (Janssen et al. Abstract DNA amplifications at 11q13 are frequently observed in esophageal squamous cell carcinoma (ESC) and correlate with a malignant phenotype. Although this amplicon spans a region of several megabases and harbors numerous genes, CCND1 and EMS1 are thought to be the relevant candidates in ESC. We investigated whether the putative transforming gene MYEOV, mapping 360 kb centromeric to CCND1 and activated concomitantly with CCND1 in a subset of t(11;14)(q13;q32) positive multiple myeloma cell lines, represents a target of 11q13 amplification in ESC. To evaluate the role of MYEOV in ESC, we tested 31 ESC cell lines and 48 primary tumors for copy number levels of MYEOV and demonstrated that MYEOV was always coamplified with CCND1. However, MYEOV expression levels correlated only inconsistently with DNA amplification data. Treatment with the demethylating agent 5-aza-2Ј-deoxycytidine restored MYEOV expression in a subset of cell lines exhibiting DNA amplification without high MYEOV expression, suggesting that MYEOV is transcriptionally silenced by a DNA methylation mechanism in most of the latter cell lines. Our results indicate that 1999, 2000) . Fine mapping of MYEOV by fluorescence in situ hybridization to extended DNA fibers showed that this gene was sublocalized 360 kb centromeric to CCND1. Interestingly, the breakpoints of MM cell lines with t(11;14) were localized within this 360-kb region between MYEOV and CCND1. Furthermore, in a subset of MM cell lines with t(11;14) and CCND1 overexpression, overexpression of MYEOV was revealed as well, suggesting that MYEOV might act as a second oncogene or as a modifier of B-cell transformation (Janssen et al. 2000) .
All these findings prompted us to examine the role of MYEOV in esophageal carcinogenesis. We therefore investigated the amplification and expression status of MYEOV together with CCND1 and EMS1 in our series of ESC cell lines as well as in primary tumors. Our results show MYEOV coamplification with CCND1 in all cell lines and primary tumors tested, whereas MYEOV expression was only detected in a subset of cell lines carrying MYEOV amplification. Additional experiments with the demethylating agent 5-aza-2Ј-deoxycytidine (5-AzaCd) suggest that MYEOV transcription is epigenetically silenced by methylation within the 11q13 amplicon.
Materials and methods

Cell lines and primary tumors of ESC
All 31 human ESC cell lines (KYSE series) were established from surgically resected tumors (Shimada et al. 1992) , and maintained in RPMI-1640 supplemented with 10% fetal calf serum. Data from comparative genomic hybridization analyses involving 29 of these lines have been reported elsewhere (Pimkhaokham et al. 2000) . After obtaining written consent from each patient as prescribed by the respective ethics committees, ESC tumor samples were collected from 48 independent patients treated at the University Hospitals of Kyoto and Keio in the formed style as approved.
Southern, dot, and Northern blot hybridizations
For Southern blot analysis, 10-µg aliquots of EcoRIdigested DNA extracted from each cell line or normal peripheral blood cells were electrophoresed in 0.8% agarose gels and transferred to nylon membranes (BIODYNE B, Nihon Pall, Tokyo, Japan). For dot blot analysis, 2-µg of DNA from each primary tumor, each cell line, or normal lymphocytes was denatured with 0.4 N NaOH, and then transferred to nylon membranes (BIODYNE B, Nihon Pall). For Northern blot analyses, 10-µg samples of total RNA extracted from each cell line were size fractionated in 1.0% agarose/0.67 M formaldehyde gels and transferred to positively charged nylon membranes (Hybond-Nϩ, Amersham Pharmacia Biotech, Tokyo, Japan).
Each membrane was hybridized with [α 32 P]-deoxycytidine triphosphate-labeled MYEOV cDNA under appropriate conditions, washed, and then exposed as described elsewhere (Janssen et al. 2000; Imoto et al. 2001a Imoto et al. , 2001b . Subsequently, membranes were hybridized with cDNA probes for CCND1, EMS1, and the human glyceraldehyde-3-phosphate dehydrogenase gene (GAPDH) as an internal standard. Autoradiographic signals were analyzed using a BAS-2500 image analyzer (Fuji film, Tokyo, Japan). After the background was subtracted, an intensity of each signal was evaluated with normalization divided by GAPDH signal for each sample.
5-AzaCd treatment
To assess reactivation of MYEOV expression, we plated seven ESC cell lines (KYSE-30, 170, 200, 510, 790, 960, and 1170) in six-well tissue culture plates 24 h before treatment. Cells were treated with 10 µM of 5-AzaCd (Sigma Chemical, St. Louis, MO, USA) as described by Kusaba et al. (1999) , and harvested after 7 days. Total RNA was extracted, electrophoresed, northern blotted, and analyzed as described earlier.
Results
Amplification of MYEOV, CCND1, and EMS1 in ESC cell lines and primary tumors
As shown in Fig. 1A , 20 of 31 (64.5%) cell lines showed coamplification of MYEOV, CCND1, and EMS1. One cell line showed small amplification of EMS1 alone (KYSE-30), and the remaining 10 cell lines (KYSE-70, 150, 170, 190, 270, 350, 450, 850, 1190, and 1440) showed no amplification of these genes. Because of a limited amount of DNA, we carried out dot blot analysis in primary ESC tumors, and identified that MYEOV and CCND1 are always coamplified in 6 of 48 tumors (12.5%) (Fig. 2) .
Differential expression pattern between MYEOV and CCND1 in ESC cell lines
Northern blot analysis revealed that all 20 cell lines with amplification of CCND1 showed its consequent overexpression. One cell line (KYSE-350) without CCND1 amplification also showed high expression of this gene. Under the same exposure conditions (24 h), MYEOV expression was detected in the KYSE-1240 cell line only (data not shown). After longer exposure (14 days), we were able to detect marked MYEOV expression levels in nine cell lines (KYSE-170, 220, 410, 450, 1240 (KYSE-170, 220, 410, 450, , 1250 (KYSE-170, 220, 410, 450, , 1260 (KYSE-170, 220, 410, 450, , 2270 (KYSE-170, 220, 410, 450, , and 2650 and low to moderate MYEOV expression levels in 7 lines (KYSE-30, 150, 270, 350, 790, 850 and 2400) (Fig. 1B) . Eleven lines 140, 180, 200, 510, 520, 590, 770, 890, 960 , and 1170) exhibiting coamplification of MYEOV and CCND1 did not show any MYEOV expression, although all of them showed elevated or high levels of CCND1 expression (Fig. 1B) . Seven cell lines showed MYEOV expression without concomitant MYEOV amplification 150, 170, 270, 350, 450, and 850) . Similar to CCND1, high expression of EMS1 was consistently observed in cell lines with its amplification, although one cell line, KYSE-450, showed high expression of EMS1 in the absence of its amplification.
Restoration of MYEOV expression after treatment with 5-AzaCd
A comparison between our Southern and Northern blot data revealed some discrepancies; for example, in some cell lines MYEOV amplification occurred without concomitant MYEOV expression. These data suggested that MYEOV expression might be regulated epigenetically; for example, by methylation. Therefore, we examined restoration of MYEOV expression in MYEOV amplification-positive/ expression-negative ESC cell lines after 5-AzaCd treatment. Seven different cell lines 170, 200, 510, 790, 960 , and 1170), of which one line (KYSE170) showed high MYEOV expression without concomitant DNA amplification, were treated with 5-AzaCd. Despite 5-AzaCd treatment, MYEOV expression levels in the KYSE-170 cell line were barely changed. On the other hand, MYEOV expression was clearly restored in most of the other cell lines (Fig. 3) . Restored MYEOV expression levels were very prominent in three cell lines (KYSE-510, 790, and 1170) , all of which showed distinct amplification of MYEOV, and their restored expression levels matched with their respective amplification levels (Fig. 3) . 
Discussion
Amplification of the chromosomal region of 11q13 is commonly observed in various human cancers, including breast, bladder, ESC, and head and neck tumors (Knuutila et al. 1998) . The amplicon involved has been reported to harbor several genes, including CCND1, FGF4 (HSTF1), FGF3 (INT2), and EMS1. Among them, the role of CCND1 and EMS1 in the formation of the amplification has been well established (Schuuring 1995) . CCND1 is located within 60 kb of FGF4 (http://www.ncbi.nlm.nih.gov/cgi-bin/ Entretz/map-search), whereas EMS1 maps at least 800 kb telomeric to CCND1 (Hui et al. 1997) . Amplification data for CCND1, FGF3, and EMS1 in a cohort of 747 breast cancers showed coamplification of CCND1 and FGF3, but not of EMS1 and CCND1, or EMS1 and FGF3 (Hui et al. 1997 ). In addition, EMS1 amplification without concomitant CCND1 and/or FGF3 amplification was reported in a significant fraction (44%). Independent amplification of CCND1 and EMS1 has been reported in other types of tumors as well (Schuuring 1995; Meredith et al. 1995; Rodrigo et al. 2000) . Consistent with those data, our results show that EMS1 could also be found amplified solely, although it was coamplified with CCND1 in most cases, whereas MYEOV was always coamplified with CCND1 in cell lines and primary tumors of ESC. Taken together, our data are consistent with an amplification core spanning at least the region between MYEOV and FGF3 in ESC. Several genes activated by DNA amplification in the 11q13 region may be located within this core region.
DNA methylation is thought to play a key role in the regulation of gene expression, and various genes show an inverse relationship between DNA methylation and transcription in both normal and malignant cells (Boyes and Bird 1992; Ponder 2001; Baylin et al. 2001) . Our results showed prominent restoration of MYEOV expression after treatment with 5-AzaCd in three cell lines (KYSE-510, 790, and 1170) , all of which exhibited distinct amplification of this gene, supporting the hypothesis that, despite its amplification, aberrant methylation of the MYEOV CpG islands inhibited its expression. Indeed, restored MYEOV expression levels were almost proportional to the level of MYEOV amplification in each of the cell lines after 5-AzaCd treatment. Because the genomic structure of the MYEOV gene, including its promoter region, has not yet been characterized, we could not evaluate the methylation status of the promoter region regulating MYEOV expression. Therefore, the possibility remains that the restored MYEOV expression by 5-AzaCd treatment may be induced indirectly via activating the expression of trans-acting factor(s) regulating MYEOV transcription. Another possible mechanism to modulate the transcription of the MYEOV gene independent of its genomic copy number would be by histone deacetylation (Struhl 1998) . Histone deacetylases (HDACs) regulate the acetylation status of the core nucleosomal histones, which regulate the transcriptional activity of certain genes, and HDAC activity is generally associated with transcriptional repression (Struhl 1998) . However, our preliminary study using Tricostatin A, a potent HDAC inhibitor, with or without 5-AzaCd, did not alter MYEOV expression, excluding this possibility (unpublished data). Further study will be necessary to determine the precise mechanisms for silencing MYEOV expression in tumor cells with its amplification.
Amplified chromosomal regions usually span a region of several megabases, consist of several amplification units, and harbor many different genes (Schuuring 1995; Schwab 1998) . However, the number of target genes activated via amplification is usually limited (Imoto et al. 2001b; Schuuring et al. 1992; Yasui et al. 2001; Nakakuki et al. 2002; Platzer et al. 2002) . Despite amplification, several genes in the amplicon are not upregulated, even though they are previously nominated candidate targets for amplification or known to be oncogenes (Platzer et al. 2002) ; the reasons have not yet been elucidated. Our results suggest that DNA methylation might be a mechanism for escaping upregulation of genes involved in amplification. Further   Fig. 3 . Northern blot analysis of MYEOV in ESC cell lines treated with or without the DNA methylation inhibitor agent 5-aza-2Ј-deoxycytidine (5-AzaCd). Cells were treated with 10 µM of 5-AzaCd or vehicle for 7 days. GAPDH served as a control probe. Note the clear reconstitution of MYEOV expression after 5-AzaCd treatment in the ESC cell lines 790 , and 1170 at levels comparable to their relative DNA amplification levels. In KYSE-960, the MYEOV expression level was partially restored, but at a level incomparable to its amplification status. In KYSE-170 exhibiting high MYEOV expression without its amplification, MYEOV expression levels were not altered after 5-AzaCd treatment studies will be necessary to clarify whether DNA methylation plays an important role in gene silencing of different genes, both within the same amplicon and among different amplicons on different chromosomes.
